Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NYSE:ATNMNASDAQ:BMEANASDAQ:COCPNASDAQ:IMRX On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeATNMActinium Pharmaceuticals$1.71-6.6%$1.43$1.03▼$8.81$53.35M-0.24501,941 shs362,979 shsBMEABiomea Fusion$1.45-7.6%$1.99$1.38▼$13.07$54.48M-0.07910,928 shs733,090 shsCOCPCocrystal Pharma$1.43-5.6%$1.45$1.12▼$3.26$14.54M2.1328,939 shs22,982 shsIMRXImmuneering$1.48-5.7%$1.41$1.00▼$3.83$53.26M-0.222.33 million shs192,103 shs7 Energy Stocks to Buy and Hold ForeverWith the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceATNMActinium Pharmaceuticals-6.56%+17.12%+42.50%+39.02%-82.55%BMEABiomea Fusion-7.64%-0.68%-15.70%-60.27%-87.48%COCPCocrystal Pharma-5.61%-2.05%+7.08%-27.04%-24.74%IMRXImmuneering-5.73%+17.46%+7.25%-13.45%-3.90%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationATNMActinium Pharmaceuticals1.2133 of 5 stars3.40.00.00.01.10.00.6BMEABiomea Fusion2.6832 of 5 stars3.50.00.00.03.13.31.3COCPCocrystal Pharma3.2022 of 5 stars3.55.00.00.03.11.70.6IMRXImmuneering2.1746 of 5 stars3.32.00.00.00.03.31.3Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceATNMActinium Pharmaceuticals 2.75Moderate Buy$4.00133.92% UpsideBMEABiomea Fusion 3.08Buy$22.601,458.62% UpsideCOCPCocrystal Pharma 3.00Buy$7.00389.51% UpsideIMRXImmuneering 2.50Moderate Buy$15.33936.04% UpsideCurrent Analyst Ratings BreakdownLatest COCP, BMEA, ATNM, and IMRX Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/15/2025BMEABiomea FusionD. Boral CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$16.00 ➝ $16.005/12/2025ATNMActinium PharmaceuticalsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$4.00 ➝ $4.005/7/2025IMRXImmuneeringOppenheimerSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOutperform ➝ Outperform$25.00 ➝ $21.005/6/2025BMEABiomea FusionHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$40.00 ➝ $18.005/6/2025BMEABiomea FusionD. Boral CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$16.00 ➝ $16.005/6/2025IMRXImmuneeringChardan CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$13.00 ➝ $13.004/28/2025ATNMActinium PharmaceuticalsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$4.00 ➝ $4.004/10/2025IMRXImmuneeringNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$12.00 ➝ $12.004/2/2025BMEABiomea FusionBarclaysSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetEqual Weight ➝ Equal Weight$11.00 ➝ $3.004/1/2025ATNMActinium PharmaceuticalsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$4.00 ➝ $4.003/31/2025BMEABiomea FusionHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$40.00 ➝ $40.00(Data available from 5/22/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookATNMActinium Pharmaceuticals$81K658.58N/AN/A$1.31 per share1.31BMEABiomea FusionN/AN/AN/AN/A$4.74 per shareN/ACOCPCocrystal PharmaN/AN/AN/AN/A$2.59 per shareN/AIMRXImmuneering$320K166.44N/AN/A$3.09 per share0.48Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateATNMActinium Pharmaceuticals-$48.82M-$1.39N/AN/AN/AN/A-100.85%-47.89%N/ABMEABiomea Fusion-$117.25M-$3.55N/AN/AN/AN/A-118.90%-93.66%7/30/2025 (Estimated)COCPCocrystal Pharma-$17.98M-$1.57N/AN/AN/AN/A-94.62%-78.24%N/AIMRXImmuneering-$53.47M-$1.96N/AN/AN/AN/A-79.19%-69.08%8/5/2025 (Estimated)Latest COCP, BMEA, ATNM, and IMRX EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/15/2025Q1 2025COCPCocrystal Pharma-$0.52-$0.23+$0.29-$0.23N/AN/A5/5/2025Q1 2025BMEABiomea Fusion-$0.84-$0.80+$0.04-$0.80N/AN/A5/5/2025Q1 2025IMRXImmuneering-$0.41-$0.42-$0.01-$0.42N/AN/A3/31/2025Q4 2024BMEABiomea Fusion-$1.00-$0.81+$0.19-$0.81N/AN/A3/27/2025Q4 2024COCPCocrystal Pharma-$0.55-$0.32+$0.23-$0.32N/AN/A3/20/2025Q4 2024IMRXImmuneering-$0.42-$0.58-$0.16-$0.58N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthATNMActinium PharmaceuticalsN/AN/AN/AN/AN/ABMEABiomea FusionN/AN/AN/AN/AN/ACOCPCocrystal PharmaN/AN/AN/AN/AN/AIMRXImmuneeringN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioATNMActinium PharmaceuticalsN/A10.2510.25BMEABiomea FusionN/A3.393.39COCPCocrystal PharmaN/A7.327.32IMRXImmuneeringN/A7.997.99Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipATNMActinium Pharmaceuticals27.50%BMEABiomea Fusion96.72%COCPCocrystal Pharma6.72%IMRXImmuneering67.65%Insider OwnershipCompanyInsider OwnershipATNMActinium Pharmaceuticals6.00%BMEABiomea Fusion27.57%COCPCocrystal Pharma28.14%IMRXImmuneering25.00%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableATNMActinium Pharmaceuticals3031.20 million29.32 millionOptionableBMEABiomea Fusion5037.57 million26.25 millionOptionableCOCPCocrystal Pharma1010.17 million7.57 millionNot OptionableIMRXImmuneering6035.99 million23.29 millionNot OptionableCOCP, BMEA, ATNM, and IMRX HeadlinesRecent News About These CompaniesImmuneering Reports First Quarter 2025 Financial Results and Provides Business UpdatesMay 5, 2025 | globenewswire.comImmuneering Co. (NASDAQ:IMRX) Short Interest UpdateMay 2, 2025 | marketbeat.comImmuneering (IMRX) Expected to Announce Quarterly Earnings on TuesdayMay 1, 2025 | marketbeat.com177,377 Shares in Immuneering Co. (NASDAQ:IMRX) Bought by Rockefeller Capital Management L.P.April 26, 2025 | marketbeat.comImmuneering to Present at the 24th Annual Needham Virtual Healthcare ConferenceApril 2, 2025 | globenewswire.comImmuneering Corporation: Immuneering Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business UpdatesMarch 21, 2025 | finanznachrichten.deImmuneering Corporation Announces Grant of Inducement AwardMarch 21, 2025 | globenewswire.comImmuneering appoints Matushansky as Chief Medical OfficerMarch 21, 2025 | markets.businessinsider.comImmuneering Corporation: Immuneering Names Dr. Igor Matushansky as Chief Medical OfficerMarch 21, 2025 | finanznachrichten.deImmuneering Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business UpdatesMarch 20, 2025 | globenewswire.comImmuneering Names Dr. Igor Matushansky as Chief Medical OfficerMarch 20, 2025 | globenewswire.comImmuneering management to meet with OppenheimerMarch 7, 2025 | markets.businessinsider.comImmuneering Slides As Insider Purchases Lose Another US$186kMarch 6, 2025 | finance.yahoo.comImmuneering and Regeneron partner on lung cancer trialFebruary 6, 2025 | msn.comImmuneering Announces Clinical Supply Agreement with Regeneron Pharmaceuticals to Evaluate IMM-1-104 in Combination with Libtayo® (cemiplimab)February 6, 2025 | finance.yahoo.comImmuneering Signs Clinical Supply Agreement With Regeneron To Evaluate IMM-1-104 Plus LibtayoFebruary 6, 2025 | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: Immuneering (IMRX) and Palatin Technologies (PTN)February 6, 2025 | markets.businessinsider.comImmuneering to Present at the Oppenheimer 35th Annual Healthcare Life Sciences ConferenceFebruary 3, 2025 | globenewswire.comImmuneering Updates On Positive Phase 2a Results For IMM-1-104 With Modified FOLFIRINOXJanuary 14, 2025 | markets.businessinsider.comMorgan Stanley Sticks to Their Sell Rating for Immuneering (IMRX)January 14, 2025 | markets.businessinsider.comImmuneering Provides Positive Update on Phase 2a Arm Studying IMM-1-104 in Combination with Modified FOLFIRINOX for First-Line Pancreatic CancerJanuary 13, 2025 | finance.yahoo.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeCOCP, BMEA, ATNM, and IMRX Company DescriptionsActinium Pharmaceuticals NYSE:ATNM$1.71 -0.12 (-6.56%) Closing price 05/21/2025 04:00 PM EasternExtended Trading$1.72 +0.01 (+0.29%) As of 05/21/2025 08:00 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Actinium Pharmaceuticals, Inc. develops antibody radiation conjugates and other targeted radiotherapies intended to improve outcomes for people who have failed existing oncology therapies. Its Iomab-B is an induction and conditioning agent prior to bone marrow transplant in patients with relapsed and refractory acute myeloid leukemia (r/r AML). The company focuses on advancing its development for product candidate Actimab-A, a therapeutic agent that has demonstrated potential activity in r/r AML patients. In addition, it engages with the National Cancer Institute under the cooperative research and development agreement for the development of Actimab-A in AML and other myeloid malignancies. Its Iomab-ACT, a next generation conditioning candidate, is being developed for improving patient access and outcomes for curative cell and gene therapies. Further, the company's research and development activities primarily focus on advancing various preclinical programs for solid tumor indications. The company holds approximately 235 patents and patent applications, including various patents related to the manufacture of the isotope Ac-225 in a cyclotron. The company is based in New York, New York.Biomea Fusion NASDAQ:BMEA$1.45 -0.12 (-7.64%) Closing price 05/21/2025 04:00 PM EasternExtended Trading$1.44 0.00 (-0.34%) As of 05/21/2025 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Biomea Fusion, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of covalent small molecule drugs to treat patients with genetically defined cancers and metabolic diseases. Its lead product candidate is BMF-219, a covalent inhibitor of menin for treating patients with liquid and solid tumors and type 2 diabetes. The company was incorporated in 2017 and is headquartered in Redwood City, California.Cocrystal Pharma NASDAQ:COCP$1.43 -0.09 (-5.61%) Closing price 05/21/2025 04:00 PM EasternExtended Trading$1.43 0.00 (0.00%) As of 05/21/2025 06:44 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Cocrystal Pharma, Inc., a biotechnology company, focuses on the discovery and development of antiviral therapeutic treatments for serious and/or chronic viral diseases. It employs structure-based technologies to create antiviral drugs primarily to treat hepatitis C virus (HCV), influenza virus, coronavirus, norovirus, and respiratory virus infections. The company develops CC-31244, a HCV non-nucleoside polymerase inhibitor that has completed Phase II a clinical trial to treat HCV infection; and CC-42344, a PB2 inhibitor that has completed Phase I clinical trial for treating influenza infection. It is also involved in identifying and developing non-nucleoside polymerase inhibitors for norovirus infections. Cocrystal Pharma, Inc. has a license and research collaboration agreement with Merck Sharp & Dohme Corp. to discover and develop proprietary influenza A/B antiviral agents; and a license agreement with Kansas State University Research Foundation to develop antiviral compounds for the treatment of norovirus and coronavirus infections. The company is headquartered in Bothell, Washington.Immuneering NASDAQ:IMRX$1.48 -0.09 (-5.73%) Closing price 05/21/2025 04:00 PM EasternExtended Trading$1.50 +0.02 (+1.01%) As of 04:49 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Immuneering Corporation, a clinical-stage oncology company, engages in the development of medicines for broad populations of cancer patients. Its lead product candidates include IMM-1-104, a dual-MEK inhibitor currently under Phase 1/2a clinical trial to treat patients with cancer, including pancreatic, melanoma, colorectal, and non-small cell lung cancer caused by mutations of RAS and/or RAF; and IMM-6-415 is in Investigational New Drug application to treat solid tumors. Immuneering Corporation was incorporated in 2008 and is based in Cambridge, Massachusetts. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Microsoft Could Rally as EU Antitrust Case Nears Resolution Canada Goose Soars 30%—Is This Rally Built to Last? Palo Alto Networks: Buy The Dip, Long-Term Tailwinds Ahead Lowe’s Stock Uptrend Can Continue for These 2 Reasons CrowdStrike Near Breakout: Is Now the Time to Buy? $30B AI Opportunity: Will It Power Meta’s Next Surge? Intel Refocuses: NEX Sale and Foundry Pivot Signal New Era Rivian Stock Below $20: Charging Up or in the Breakdown Lane? Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
